In an 8‑week pregnant woman with mild obstructive sleep‑disordered breathing (AHI 2–9 depending on desaturation criteria), frequent snoring, 42% supine sleep, and a low Epworth Sleepiness Scale score, is a mandibular advancement device an appropriate treatment option?

Mandibular Advancement Device is NOT Appropriate for This Pregnant Patient

A mandibular advancement device (MAD) should not be used in this 8-week pregnant woman with mild sleep-disordered breathing; instead, she requires close monitoring and consideration of CPAP therapy only if her condition worsens or symptoms develop, as pregnancy-specific management takes precedence over standard OSA treatment algorithms.

Why MAD is Inappropriate in This Clinical Context

Pregnancy Changes the Treatment Paradigm Entirely

This patient's pregnancy fundamentally alters the risk-benefit calculation. While MAD is indicated for mild-moderate OSA in non-pregnant adults 1, 2, pregnancy introduces unique maternal-fetal considerations that override standard OSA treatment guidelines. The primary concern is not her current mild symptoms (ESS 4/24 is normal), but rather the potential for progression and pregnancy-related complications 3, 4.

Her Current Clinical Picture Does Not Warrant Treatment

• AHI of 2 (using 4% desaturation) or 9 (using 3% desaturation) represents borderline to mild OSA
• ESS of 4/24 is well below the threshold for excessive daytime sleepiness (normal is <10)
• No cardiovascular symptoms or complications currently present
• Her increased napping is physiologically normal for early pregnancy, not pathological sleepiness

The 2015 AASM guideline recommends MAD for patients with mild-moderate OSA who are symptomatic or CPAP-intolerant 2. This patient is neither symptomatic (ESS 4) nor has she tried CPAP, so MAD indication criteria are not met.

Pregnancy-Specific Risks Demand Different Approach

Sleep-disordered breathing in pregnancy is associated with preeclampsia, gestational hypertension, and gestational diabetes 4, 5, 6, 7. The 2026 ACCP guideline on OSA in pregnancy recommends treatment for pregnant patients with AHI ≥15 regardless of symptoms, OR AHI 5-15 with symptoms/comorbidities 8.

This patient falls into a gray zone: Her AHI is 2-9 depending on criteria, and she lacks significant symptoms or current comorbidities. However, the ACCP guideline specifically recommends autotitrating PAP therapy as the preferred treatment when intervention is needed 8—not MAD.

Why CPAP Over MAD in Pregnancy

When treatment becomes necessary in pregnancy:

• CPAP is the established therapy with pregnancy safety data 4, 6, 8
• MAD has no pregnancy-specific efficacy or safety studies
• CPAP can be rapidly titrated as pregnancy progresses (OSA typically worsens in third trimester)
• Autotitrating PAP is specifically recommended for pregnant patients requiring treatment 8

The case report from Poland demonstrates dramatic improvement in both OSA (AHI 82→1.2) and blood pressure normalization with CPAP in severe pregnancy-related OSA 6, illustrating CPAP's effectiveness and safety profile.

Recommended Management Algorithm

Immediate Actions (8 Weeks Gestation)

1. No active OSA treatment currently indicated given low AHI and absence of symptoms
2. Optimize thyroid management (her Synthroid dosing is erratic—100 mcg some days, less on others—which needs standardization)
3. Counsel on sleep position: She already sleeps supine 42% of the time; encourage left lateral positioning to improve venous return and potentially reduce AHI

Monitoring Strategy Through Pregnancy

• Repeat screening at 28-32 weeks gestation when OSA risk peaks 3, 8
• Watch for development of:
  • Gestational hypertension or preeclampsia
  • Gestational diabetes
  • Worsening snoring or witnessed apneas
  • Development of true excessive daytime sleepiness (ESS >10)
  • Any cardiovascular symptoms

Treatment Thresholds During Pregnancy

Initiate CPAP (not MAD) if any of the following develop 8:

• AHI increases to ≥15 on repeat testing
• AHI 5-15 with development of hypertension, preeclampsia, or gestational diabetes
• ESS increases to >10 with functional impairment
• Oxygen desaturations become more severe (nadir <88%)

Postpartum Reassessment

Retest 3-6 months postpartum 8 as pregnancy-related OSA often resolves, and treatment decisions can be revisited in the non-pregnant state when MAD would become a reasonable option if OSA persists.

Critical Pitfalls to Avoid

• Do not extrapolate non-pregnancy OSA guidelines directly to pregnant patients—the evidence base and risk-benefit calculations differ substantially
• Do not dismiss her increased napping as pathological—this is normal first-trimester physiology, not OSA-related hypersomnolence
• Do not delay treatment if she develops preeclampsia or gestational hypertension—these are strong indications for CPAP therapy regardless of AHI severity 6, 7
• Do not use MAD as a "gentler" alternative in pregnancy—there is no safety or efficacy data, and CPAP is the evidence-based choice when treatment is needed

Why Guidelines Support This Approach

The 2025 Portuguese consensus confirms MAD is indicated for mild-moderate OSA in non-pregnant adults and as CPAP alternative 1. The 2015 AASM guideline similarly positions MAD for symptomatic patients or CPAP-intolerant individuals 2. However, neither guideline addresses pregnancy, and the pregnancy-specific 2026 ACCP guideline explicitly recommends autotitrating PAP when treatment thresholds are met 8.

The absence of MAD in pregnancy guidelines is telling—when expert panels specifically addressed OSA in pregnancy, they did not include MAD as a treatment option, instead focusing on PAP therapy with established safety profiles 8.